NDLI: Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.

Please wait, while we are loading the content...

Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.

Content Provider	Europe PMC
Author	Beara-Lasic, Lada Pillinger, Michael H Goldfarb, David S
Copyright Year	2010
Abstract	Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only effective for the subset of patients with better kidney function. Allopurinol use is limited due to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and failure to achieve targeted serum urate levels. In part this failure may be due to the necessity for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may offer several advantages and can be given as an alternative to allopurinol. We review the basic biology and clinical performance of febuxostat, and consider the potential utility of this agent in comparison to the older, better-established gout therapeutics.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC3108781&blobtype=pdf
Journal	International Journal of Nephrology and Renovascular Disease [Int J Nephrol Renovasc Dis]
Volume Number	3
PubMed Central reference number	PMC3108781
PubMed reference number	21694922
e-ISSN	11787058
DOI	10.2147/ijnrd.s5563
Language	English
Publisher	Dove Medical Press
Publisher Date	2010-02-09
Access Restriction	Open
Rights License	This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. © 2010 Beara-Lasic et al, publisher and licensee Dove Medical Press Ltd.
Subject Keyword	allopurinol gout suppressants nephrolithiasis uric acid urolithiasis
Content Type	Text
Resource Type	Article
Subject	Nephrology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in